Home > Information > News

Biomedical materials giant, with revenue exceeding 3 billion!

TK Bio-based Materials and Energy 2025-03-21 09:41:02

On the evening of March 19, Aimeike Technology Development Co., Ltd. (hereinafter referred to as "Aimeike", 300896) released its annual report for 2024. In 2024, Aimeike achieved a revenue of 3.026 billion yuan, an increase of 5.45% year-on-year; it realized a total profit of 2.281 billion yuan, an increase of 5.82% year-on-year; and it achieved a net profit of 1.956 billion yuan, an increase of 5.47% year-on-year. The company's total assets at the end of the period were 8.34 billion yuan, an increase of 1.488 billion yuan from the beginning of the period.

Aimeike stated in the annual report that the profit distribution plan approved by this board meeting is to distribute a cash dividend of 38 yuan (including tax) for every 10 shares, based on 301,426,187 shares, with a total cash dividend of approximately 1.145 billion yuan (including tax). The amount of cash dividends accounts for 58.51% of the net profit attributable to the parent company's shareholders in the consolidated financial statements for the year 2024, setting a record for the highest dividend since the company's listing.

Two pillar products perform impressively

In 2024, both of Imeik's two pillar products, solution-based and gel-based injectable products, achieved year-on-year growth. Among them, the revenue from solution-based injectable products reached 1.744 billion yuan, an increase of 4.40% compared to the same period last year; the revenue from gel-based injectable products reached 1.216 billion yuan, an increase of 5.01% compared to the same period last year.

The announcement shows that Imeik is one of the earliest companies in China to conduct independent research and development of biomedical materials for medical aesthetics. Currently, the company has 11 Class III medical device products approved by the National Medical Products Administration, including six series of hyaluronic acid-based dermal fillers, one poly-L-lactic acid-based dermal filler, one PPDO facial埋线产品翻译为buried thread product，其余部分保持不变。 The announcement shows that Imeik is one of the earliest companies in China to conduct independent research and development of biomedical materials for medical aesthetics. Currently, the company has 11 Class III medical device products approved by the National Medical Products Administration, including six series of hyaluronic acid-based dermal fillers, one poly-L-lactic acid-based dermal filler, one PPDO buried thread product, one product suitable for tissue repair and healing, and two disposable sterile injection needles.

At present, Imeik is shifting its focus from localized anti-aging to comprehensive anti-aging. In 2024, Imeik's R&D expenses reached 3.04 billion yuan, accounting for 10.04% of its revenue. By the end of 2024, Imeik held 163 valid authorized patents, including 49 invention patents.

Among them, semaglutide injection, deoxycholic acid injection, and recombinant hyaluronidase have received clinical trial approvals from the National Medical Products Administration; the marketing authorization applications for botulinum toxin type A for injection, minoxidil solution, and lidocaine-prilocaine cream have been accepted and entered the review stage. At the same time, the company has also established strategic partnerships with top research institutions at home and abroad, introducing cutting-edge technological achievements to accelerate product iteration and upgrading.

accelerate the internationalization process

Aimike also sets its sights on the global market. Recently, Aimike announced that through its wholly-owned subsidiary "Aimike Hong Kong" and "Shourui Hong Kong," they have jointly established "Aimike International," which plans to acquire 85% of the equity in South Korea's REGEN Biotech, Inc. for $190 million, marking a new phase in Aimike's internationalization strategy.

Regen company, as a leading medical aesthetics product enterprise in South Korea, possesses globally leading polylactic acid-based dermal filler technology. Its flagship products, AestheFill and PowerFill, have received registration approvals in 34 and 24 countries and regions respectively, with high market recognition. By integrating Regen's technological advantages, product pipeline, and international market resources, IMEIK is expected to quickly address the shortcomings of its overseas channels, forming a dual-driven model of "technology + market."

【Copyright and Disclaimer】The above information is collected and organized by PlastMatch. The copyright belongs to the original author. This article is reprinted for the purpose of providing more information, and it does not imply that PlastMatch endorses the views expressed in the article or guarantees its accuracy. If there are any errors in the source attribution or if your legitimate rights have been infringed, please contact us, and we will promptly correct or remove the content. If other media, websites, or individuals use the aforementioned content, they must clearly indicate the original source and origin of the work and assume legal responsibility on their own.

Biomedical materials giant, with revenue exceeding 3 billion!

Most Popular